

## GENTAMICIN SULFATE- gentamicin sulfate solution/ drops Redpharm Drug


-----

### GENTAMICIN SULFATE ophthalmic solution, USP 0.3% sterile

#### DESCRIPTION

Gentamicin sulfate ophthalmic solution, USP is a sterile, topical anti-infective agent for ophthalmic use.

Gentamicin is obtained from cultures of *Micromonospora purpurea*. It is a mixture of the sulfate salts of gentamicin C<sub>1</sub>, C<sub>2</sub>, and C<sub>1A</sub>. All three components appear to have similar antimicrobial activity. Gentamicin sulfate occurs as a white to buff powder and is soluble in water and insoluble in alcohol. The structural formula is as follows:



**Each mL contains: Active:**gentamicin sulfate equivalent to 3 mg (0.3%) gentamicin base. **Preservative:**benzalkonium chloride. **Inactives:**edetate disodium; polyvinyl alcohol 1.4%; purified water; sodium chloride; sodium phosphate, dibasic; and hydrochloric acid and/or sodium hydroxide may be added to adjust pH. The solution is an aqueous, buffered solution with a shelf life pH range of 6.5 to 7.5.

#### CLINICAL PHARMACOLOGY

##### Microbiology

Gentamicin sulfate is active *in vitro* against many strains of the following microorganisms: *Staphylococcus aureus*, *Staphylococcus epidermidis*, *Streptococcus pyogenes*, *Streptococcus pneumoniae*, *Enterobacter aerogenes*, *Escherichia coli*, *Haemophilus influenzae*, *Klebsiella pneumoniae*, *Neisseria gonorrhoeae*, *Pseudomonas aeruginosa*, and *Serratia marcescens*.

#### INDICATIONS AND USAGE

Gentamicin sulfate ophthalmic solution, USP is indicated in the topical treatment of ocular bacterial infections including conjunctivitis, keratitis, keratoconjunctivitis, corneal ulcers, blepharitis, blepharoconjunctivitis, acute meibomianitis, and dacryocystitis, caused by

susceptible strains of the following microorganisms: *Staphylococcus aureus*, *Staphylococcus epidermidis*, *Streptococcus pyogenes*, *Streptococcus pneumoniae*, *Enterobacter aerogenes*, *Escherichia coli*, *Haemophilus influenzae*, *Klebsiella pneumoniae*, *Neisseria gonorrhoeae*, *Pseudomonas aeruginosa*, and *Serratia marcescens*.

## **CONTRAINDICATIONS**

Gentamicin sulfate ophthalmic solution, USP is contraindicated in patients with known hypersensitivity to any of its components.

## **WARNINGS**

### **NOT FOR INJECTION INTO THE EYE.**

Gentamicin sulfate ophthalmic solution, USP is not for injection. It should never be injected subconjunctivally, nor should it be directly introduced into the anterior chamber of the eye.

## **PRECAUTIONS**

### **General**

Prolonged use of topical antibiotics may give rise to overgrowth of nonsusceptible microorganisms, including fungi. Bacterial resistance to gentamicin may also develop. If purulent discharge, inflammation or pain becomes aggravated, the patient should discontinue use of the medication and consult a physician.

If irritation or hypersensitivity to any component of the drug develops, the patient should discontinue use of this preparation and appropriate therapy should be instituted.

### **Information for Patients**

To avoid contamination, do not touch tip of container to the eye, eyelid or any surface.

### **Carcinogenesis, Mutagenesis, Impairment of Fertility**

There are no published carcinogenicity or impairment of fertility studies on gentamicin. Aminoglycoside antibiotics have been found to be non-mutagenic.

### **Pregnancy**

Gentamicin has been shown to depress body weights, kidney weights and median glomerular counts in newborn rats when administered systemically to pregnant rats in daily doses approximately 500 times the maximum recommended ophthalmic human dose. There are no adequate and well-controlled studies in pregnant women. Gentamicin should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

### **Pediatric Use**

Safety and effectiveness in neonates have not been established.

## **ADVERSE REACTIONS**

Bacterial and fungal corneal ulcers have developed during treatment with gentamicin ophthalmic preparations.

The most frequently reported adverse reactions are ocular burning and irritation upon drug instillation, non-specific conjunctivitis, conjunctival epithelial defects and conjunctival hyperemia.

Other adverse reactions which have occurred rarely are allergic reactions, thrombocytopenic purpura and hallucinations.

## **DOSAGE AND ADMINISTRATION**

Instill one or two drops into the affected eye(s) every four hours. In severe infections, dosage may be increased to as much as two drops every hour.

## **HOW SUPPLIED**

Gentamicin sulfate ophthalmic solution, USP 0.3% is supplied sterile in white opaque LDPE plastic bottles and tips with beige high impact polystyrene (HIPS) caps as follows:

5 mL in 10 mL bottle - NDC 60758-188-05

### **Storage:**

Store at or below 25°C (77°F). Avoid exposure to excessive heat (40°C/104°F or above).

### **Revised: 10/2017**

Distributed for: Allergan USA, Inc.  
Madison, NJ 07940

©2017 Allergan. All rights reserved.

All trademarks are the property of their respective owners.

Made in the U.S.A.

v1.0USPI188

## **PRINCIPAL DISPLAY PANEL**

NDC 60758-188-05

GENTAMICIN

SULFATE

ophthalmic


solution, USP

0.3%

5 mL

sterile

Rx Only



## GENTAMICIN SULFATE

gentamicin sulfate solution/ drops

### Product Information

#### Product Type

HUMAN PRESCRIPTION  
DRUG

#### Item Code (Source)

NDC:67296-0370(NDC:60758-188)

#### Route of Administration

OPHTHALMIC

### Active Ingredient/Active Moiety

Ingredient Name	Basis of Strength	Strength
<b>GENTAMICIN SULFATE</b> (UNII: 8X7386QLV) (GENTAMICIN - UNII:T6Z9V48IKG)	GENTAMICIN	3 mg in 1 mL

### Inactive Ingredients

Ingredient Name	Strength
<b>EDETATE DISODIUM</b> (UNII: 7FLD91C86K)	
<b>POLYVINYL ALCOHOL, UNSPECIFIED</b> (UNII: 532B59J990)	
<b>WATER</b> (UNII: 059QF0KO0R)	
<b>SODIUM CHLORIDE</b> (UNII: 451W47IQ8X)	
<b>SODIUM PHOSPHATE, DIBASIC</b> (UNII: GR686LBA74)	
<b>BENZALKONIUM CHLORIDE</b> (UNII: F5UM2KM3W7)	
<b>HYDROCHLORIC ACID</b> (UNII: QTT17582CB)	
<b>SODIUM HYDROXIDE</b> (UNII: 55X04QC32I)	

### Packaging

#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:67296-0370-1	1 in 1 CARTON	01/05/1998	
1		5 mL in 1 BOTTLE, DROPPER; Type 0: Not a Combination Product		

### Marketing Information

Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
ANDA	ANDA062452	01/05/1998	

**Labeler** - Redpharm Drug (828374897)

### Establishment

Name	Address	ID/FEI	Business Operations
Redpharm Drug		828374897	repack(67296-0370)

Revised: 6/2024

Redpharm Drug